https://www.marketscreener.com/quote/stock/MABWELL-SHANGHAI-BIOSCIEN-149076099/news/Mabwell-Announces-the-Cde-Approval-of-Novel-Nectin-4-Targeting-Adc-for-Phase-III-Clinical-Trial-45542033/?utm_source=telegram&utm_medium=social&utm_campaign=share